Samsung Biologics, South Korea’s leading biotech company, announced it has signed a 1.8 trillion-won ($1.29 billion) contract to provide manufacturing services for a U.S. pharmaceutical company through 2029. The client’s name was not disclosed.
With this agreement, the firm’s cumulative contract manufacturing value for 2025 has exceeded $3.6 billion.
Samsung Biologics said it has been able to win significant global deals this year by meeting the evolving needs of clients in Asia, Europe, and the United States. The company currently partners with 17 of the world’s top 20 pharmaceutical firms and continues to extend contracts with existing clients to support the development of new therapies.
Headquartered in Songdo, near Seoul, Samsung Biologics operates five biopharmaceutical plants, with three additional facilities under construction and slated for completion by 2032. The company’s current combined annual production capacity of 784,000 liters is expected to expand to 1.324 million liters once the new plants become operational.
In its April–June results, Samsung Biologics reported a 2% year-on-year rise in net profit to 324.4 billion won ($235.1 million). Operating profit grew 9.5% to 475.6 billion won, and sales increased 11.5% to 1.28 trillion won. However, the net profit fell short of analyst expectations, with Yonhap Infomax estimating 354.8 billion won.
For the first half of 2025, sales totaled 2.59 trillion won, while operating profit reached 962.3 billion won, both higher than the same period last year. The company attributed its second-quarter growth to steady operations at Plants 1–3 and accelerated production at Plant 4.